Spots Global Cancer Trial Database for Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
Official Title: A Phase I/Ib, Open-label, Multi-center Dose Escalation Study of NIS793 in Combination With PDR001 in Adult Patients With Advanced Malignancies
Study ID: NCT02947165
Study Description
Brief Summary: To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sarah Cannon Research Institute SC, Nashville, Tennessee, United States
Huntsman Cancer Institute SC, Salt Lake City, Utah, United States
Novartis Investigative Site, Salzburg, , Austria
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Ulm, , Germany
Novartis Investigative Site, Wuerzburg, , Germany
Novartis Investigative Site, Hong Kong, , Hong Kong
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Rozzano, MI, Italy
Novartis Investigative Site, Kashiwa, Chiba, Japan
Novartis Investigative Site, St. Gallen, , Switzerland
Novartis Investigative Site, Taipei, , Taiwan
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
